Framingham biotech company BERG released a new study revealing a new test improving diagnosis of prostate cancer, according to a Thursday press release.
The study, which included 750 patients from the U.S. and Canada, showed the new technology is capable of distinguishing prostate cancer from benign prostate hyperplasia. It can also reduce the need for biopsy and prevent false negative tests.
Prostate cancer is one of the leading causes of cancer deaths in men, Dr. Niven Narain, CEO and co-founder of BERG, said in a statement.
From 2006 to 2009, Medicare spent $450 million annually on prostate screening and diagnostic procedures, according to the press release.
BERG combines artificial intelligence and biotechnology to advance treatments in oncology, neurology, and rare disease.
